Screening for cognitive symptoms among cancer patients during chemotherapy: Sensitivity and specificity of a single item self-report cognitive change score

Joanna E Fardell, Victoria Bray, Melanie L Bell, Brooke Rabe, Haryana Dhillon, Janette L Vardy, Joanna E Fardell, Victoria Bray, Melanie L Bell, Brooke Rabe, Haryana Dhillon, Janette L Vardy

Abstract

Objectives: Cognitive symptoms are commonly reported among cancer patients and survivors, yet guidance on when self-reported cognitive symptoms warrant follow-up is lacking. We sought to establish cut-off scores for identifying patients with perceived low cognitive functioning on widely used self-report measures of cognition and a novel single item Cognitive Change Score.

Methods: Adult patients diagnosed with invasive cancer who had completed at least one cycle of chemotherapy completed a questionnaire containing the EORTC-Cognitive Function (CF) subscale, Functional Assessment of Cancer Therapy-Cognitive Function (FACT-COG) Perceived Cognitive Impairment (PCI) and our Cognitive Change Score (CCS). We used receiver operating characteristic analyses to establish the discriminative ability of these measures against the Patient's Assessment of Own Functioning Inventory (PAOFI) as our reference standard. We chose cut-off scores on each measure that maximised both sensitivity and specificity for identifying patients with self-reported low CF.

Results: We recruited 294 participants (55.8% women, mean age 56.6 years) with mixed cancer diagnoses (25.5 months since diagnosis). On the CCS, 77.6% reported some cognitive change since starting chemotherapy. On the PAOFI 36% had low CF. The following cut-off scores identified cases of low CF: ≥28.5 on the CCS (75.5% sensitivity, 67.6% specificity); ≤75.0 on the European Organisation for Research and Treatment of Cancer, QLQ-C30 Cognitive Functioning scale (90.9% sensitivity, 57.1% specificity); ≤55.1 on the FACT-COG PCI-18 (84.8% sensitivity, 76.2% specificity), and ≤59.5 on the FACT-COG PCI-20 (78.8% sensitivity, 84.1% specificity).

Conclusions: We found a single item question asking about cognitive change has acceptable discrimination between patients with self-reported normal and low CF when compared to other more comprehensive self-report measures of cognitive symptoms. Further validation work is required.

Keywords: cancer; cancer-related cognitive impairment; cognition; concentration; memory; neuropsychology; psycho-oncology; screening.

© 2022 The Authors. Psycho-Oncology published by John Wiley & Sons Ltd.

References

    1. Boykoff N, Moieni M, Subramanian SK. Confronting chemobrain: an in‐depth look at survivors' reports of impact on work, social networks, and health care response. J Cancer Surviv. 2009;3(4):223. 10.1007/s11764-009-0098-x
    1. Janelsins MC, Kesler SR, Ahles TA, Morrow GR. Prevalence, mechanisms, and management of cancer‐related cognitive impairment. Int Rev Psychiatry. 2014;26(1):102‐113. 10.3109/09540261.2013.864260
    1. Lange M, Joly F, Vardy J, et al. Cancer‐related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. Ann Oncol. 2019;30(12):1925‐1940. 10.1093/annonc/mdz410
    1. Kesler S, Janelsins M, Koovakkattu D, et al. Reduced hippocampal volume and verbal memory performance associated with interleukin‐6 and tumor necrosis factor‐alpha levels in chemotherapy‐treated breast cancer survivors. Brain Behav Immun. 2013;30(Suppl l):S109‐S116. 10.1016/j.bbi.2012.05.017
    1. Dumas JA, Makarewicz J, Schaubhut GJ, et al. Chemotherapy altered brain functional connectivity in women with breast cancer: a pilot study. Brain Imaging Behav. 2013;7(4):524‐532. 10.1007/s11682-013-9244-1
    1. Pullens MJ, De Vries J, Roukema JA. Subjective cognitive dysfunction in breast cancer patients: a systematic review. Psycho‐Oncol. 2010;19(11):1127‐1138. 10.1002/pon.1673
    1. Costa DSJ, Fardell JE. Why are objective and perceived cognitive function weakly correlated in patients with cancer? J Clin Oncol. 2019;37(14):1154‐1158. 10.1200/jco.18.02363
    1. Janelsins MC, Heckler CE, Peppone LJ, et al. Cognitive complaints in survivors of breast cancer after chemotherapy compared with age‐matched controls: an analysis from a nationwide, multicenter, prospective longitudinal study. J Clin Oncol. 2017;35(5):506‐514. 10.1200/jco.2016.68.5826
    1. Dhillon HM, Tannock IF, Pond GR, Renton C, Rourke SB, Vardy JL. Perceived cognitive impairment in people with colorectal cancer who do and do not receive chemotherapy. J Cancer Surviv. 2018;12(2):178‐185. 10.1007/s11764-017-0656-6
    1. Amidi A, Christensen S, Mehlsen M, Jensen AB, Pedersen AD, Zachariae R. Long‐term subjective cognitive functioning following adjuvant systemic treatment: 7‐9 years follow‐up of a nationwide cohort of women treated for primary breast cancer. Br J Cancer. 2015;113(5):794‐801. 10.1038/bjc.2015.243
    1. Henneghan AM, Van Dyk K, Kaufmann T, et al. Measuring self‐reported cancer‐related cognitive impairment: recommendations from the cancer neuroscience initiative working group. J Natl Cancer Inst. 2021;113(12):1625‐1633. 10.1093/jnci/djab027
    1. Bray VJ, Dhillon HM, Vardy JL. Systematic review of self‐reported cognitive function in cancer patients following chemotherapy treatment. J Cancer Surviv. 2018;12(4):537‐559. 10.1007/s11764-018-0692-x
    1. Dyk KV, Crespi CM, Petersen L, Ganz PA. Identifying cancer‐related cognitive impairment using the FACT‐cog perceived cognitive impairment. JNCI Cancer Spectr. 2019;4(1). 10.1093/jncics/pkz099
    1. Wagner L, Sweet J, Butt Z, Lai J, Cella D. Measuring patient self‐reported cognitive function: development of the functional assessment of cancer therapy ‐ cognitive function instrument. J Support Oncol. 2009;7(6):W32‐W39.
    1. Rothrock NE, Cook KF, O’Connor M, Cella D, Smith AW, Yount SE. Establishing clinically‐relevant terms and severity thresholds for patient‐reported outcomes measurement information system® (PROMIS®) measures of physical function, cognitive function, and sleep disturbance in people with cancer using standard setting. Qual Life Res. 2019;28(12):3355‐3362. 10.1007/s11136-019-02261-2
    1. Terwee CB, Peipert JD, Chapman R, et al. Minimal important change (MIC): a conceptual clarification and systematic review of MIC estimates of PROMIS measures. Qual Life Res. 2021;30(10):1‐26. 10.1007/s11136-021-02925-y
    1. Mercieca‐Bebber R, Costa DS, Norman R, et al. The EORTC quality of life questionnaire for cancer patients (QLQ‐C30): Australian general population reference values. Med J Aust. 2019;210(11):499‐506. 10.5694/mja2.50207
    1. vanDam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high‐risk breast cancer: high‐dose versus standard‐dose chemotherapy. J Natl Cancer Inst. 1998;90(3):210‐218. 10.1093/jnci/90.3.210
    1. Jacobs SR, Jacobsen PB, Booth‐Jones M, Wagner LI, Anasetti C. Evaluation of the functional assessment of cancer therapy cognitive scale with hematopoietic stem cell transplant patients. J Pain Symptom Manag. 2007;33(1):13‐23. 10.1016/j.jpainsymman.2006.06.011
    1. Vardy JL, Liew A, Warby A, et al. On the receiving end: have patient perceptions of the side‐effects of cancer chemotherapy changed since the twentieth century? Support Care Cancer. 2022;30(4):3503‐3512. 10.1007/s00520-022-06804-1
    1. Chelune GJ, Heaton RK, Lehman RA. Neuropsychological and personality correlates of patients’ complaints of disability. Advances in Clinical Neuropsychology. Springer; 1986:95‐126.
    1. Bell MJ, Terhorst L, Bender CM. Psychometric analysis of the patient assessment of own functioning inventory in women with breast cancer. J Nurs Meas. 2013;21(2):320‐334. 10.1891/1061-3749.21.2.320
    1. Van Dyk K, Ganz PA, Ercoli L, Petersen L, Crespi CM. Measuring cognitive complaints in breast cancer survivors: psychometric properties of the patient's assessment of own functioning inventory. Support Care Cancer. 2016;24(12):4939‐4949. 10.1007/s00520-016-3352-6
    1. Koch V, Wagner LI, Green HJ. Assessing neurocognitive symptoms in cancer patients and controls: psychometric properties of the FACT‐Cog3. Curr Psychol. 2021. 10.1007/s12144-021-02088-6
    1. Costa DSJ, Loh V, Birney DP, et al. The structure of the FACT‐cog v3 in cancer patients, students, and older adults. J Pain Symptom Manag. 2018;55(4):1173‐1178. 10.1016/j.jpainsymman.2017.12.486
    1. Aaronson NK, Ahmedzai S, Bergman B, et al. The European organization for research and treatment of Cancer QLQ‐C30: a quality‐of‐life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365‐376. 10.1093/jnci/85.5.365
    1. Fayers PMAN, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC. Quality of Life Group. The EORTC QLQ‐C30 Scoring Manual. European Organisation for Research and Treatment of Cancer. 3rd ed. 2001.
    1. Blackstone K, Moore D, Heaton R, et al. Diagnosing symptomatic HIV‐associated neurocognitive disorders: self‐report versus performance‐based assessment of everyday functioning. J Int Neuropsychological Soc. 2012;18(1):79‐88. 10.1017/s135561771100141x
    1. Woods SP, Rippeth JD, Frol AB, et al. Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. J Clin Exp Neuropsychol. 2004;26(6):759‐778. 10.1080/13803390490509565
    1. Ganz PA, Kwan L, Castellon SA, et al. Cognitive complaints after breast cancer treatments: examining the relationship with neuropsychological test performance. J Natl Cancer Inst. 2013;105(11):791‐801. 10.1093/jnci/djt073
    1. Tavakol M, Dennick R. Making sense of Cronbach's alpha. Int J Med Educ. 2011;2:53‐55. 10.5116/ijme.4dfb.8dfd
    1. Mandrekar JN. Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol. 2010;5(9):1315‐1316. 10.1097/jto.0b013e3181ec173d
    1. Hosmer DW, Jr , Lemeshow S, Sturdivant RX. Applied Logistic Regression. John Wiley & Sons; 2013.
    1. Wieneke M, Dienst E. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho‐oncol. 1995;4(1):61‐66. 10.1002/pon.2960040108
    1. Osoba D. Health‐related quality of life and cancer clinical trials. Ther Adv Med Oncol. 2011;3(2):57‐71. 10.1177/1758834010395342
    1. Cutillo A, O'Hea E, Person S, Lessard D, Harralson T, Boudreaux E. The distress thermometer: cutoff points and clinical use. Oncol Nurs Forum. 2017;44(3):329‐336. 10.1188/17.onf.329-336
    1. Scanlon B, Brough M, Wyld D, Durham J. Equity across the cancer care continuum for culturally and linguistically diverse migrants living in Australia: a scoping review. Glob Health. 2021;17(1):87. 10.1186/s12992-021-00737-w
    1. Mitchell AJ. Screening for cancer‐related distress: when is implementation successful and when is it unsuccessful? Acta Oncol. 2013;52(2):216‐224. 10.3109/0284186x.2012.745949
    1. Van Dyk K, Ganz PA, Ercoli L, Petersen L, Crespi CM. Measuring cognitive complaints in breast cancer survivors: psychometric properties of the patient’s assessment of own functioning inventory. Support Care Cancer. 2016;24(12):4939‐4949. 10.1007/s00520-016-3352-6

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir